Residual inflammation risk affects outcomes after percutaneous coronary intervention
(European Society of Cardiology) Patients who have persistently high levels of inflammation following percutaneous coronary intervention (PCI) for coronary artery disease are significantly more likely to die from any cause or to have a heart attack within a year, according to a study of 7,026 patients published in the European Heart Journal.
ConclusionsIn these patients with T2DM, cangrelor was comparable to clopidogrel in terms of efficacy at 48 h following PCI. However, it was associated with significantly higher mild GUSTO bleeding and major and minor ACUITY bleeding, therefore requiring further workups on its safety side. This hypothesis should be explored further and confirmed in other forthcoming trials based strictly on patients wit h T2DM.
gro G Abstract Background: Combination of dual antiplatelet (DAPT) and oral anticoagulation therapy is required to decrease cardioembolic stroke and stent thrombosis risk in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). We compared the safety and efficacy of dabigatran etexilate with vitamin K antagonist (VKA), in combination with DAPT (aspirin plus clopidogrel) treatment in AF patients who underwent percutaneous coronary intervention (PCI) with stenting for ACS. Methods: Consecutive nonvalvular AF patients who received twice-daily dabigatran 110 mg (n = 389) or VKA (n = 510) and D...
ConclusionFollowing acute myocardial infarction in human patient, IMH appears to be strongly correlated with inflammatory biomarkers. Targeting the couple IMH/inflammation could be a novel strategy in future adjunctive STEMI treatment.
ConclusionThis model allows an accurate description of necrosis biomarkers kinetics following STEMI, which only few measurements. Estimated parameters, particularly CK peak concentration and the total amount of cTnT released by the injured myocardium, were highly correlated to IS measured by cardiac MRI. This method may be used in future clinical trials on the assessment of therapies aiming to reduce IS, such as conditioning therapies.
Authors: Han L, Zhang JJ, Jing HF, Qin L Abstract Acute ST-segment elevation myocardial infarction (STEMI) is one of the most common cardiovascular emergencies. With the improvement of living standards, the incidence and mortality rate of STEMI has shown a significant growth trend. PMID: 30892000 [PubMed - as supplied by publisher]
ConclusionSSRI use was associated with a significant decrease in MACE rates compared with patients receiving mirtazapine. Bleeding risk was not affected by either antidepressant treatment. SSRIs may have cardioprotective benefits compared with mirtazapine.
CONCLUSIONS: The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. PMID: 30888959 [PubMed - as supplied by publisher]
Publication date: April 2019Source: Revista Española de Cardiología (English Edition), Volume 72, Issue 4Author(s): Juan Sanchis, Sergio García-Blas, Luis Ortega-Paz, Ana Paula Dantas, Enrique Rodríguez, Lidia Abellán, Salvatore Brugaletta, Ernesto Valero, Gema Miñana, Manuel Garabito, África Corchón, Julio Núñez, Arturo Carratalá, Manel SabatéAbstractIntroduction and objectivesCell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate...
It is unclear whether universal access to primary percutaneous coronary intervention (pPCI) may reduce sex differences in 1-year rehospitalization for heart failure (HF) and myocardial infarction (MI) after ST-elevation myocardial infarction (STEMI). We studied 7,597 consecutive STEMI patients (13.8% women, N=1,045) who underwent pPCI from January 2007 to December 2013. Cox regression models adjusted for competing risk from death were used to assess sex differences in rehospitalization for HF and MI within 1 year from discharge.
Limited data on sex differences by ethnicity following percutaneous coronary intervention (PCI) exist. In this prospective cohort study, we examined sex differences in 1-year outcomes among patients from 4 ethnic groups who underwent PCI from 2010-2016 at a tertiary center. The primary outcome was 1-year major adverse cardiovascular events (MACE) defined as composite of all-cause death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR).Secondary outcomes included composite of death or MI and individual components of MACE.